Navigation Links
Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women

FRIMLEY, SURREY, England, April 30, 2007 /PRNewswire-FirstCall/ --

- Femara reduces the risk of breast cancer spreading to the lungs, the brain or the bone which has a worse prognosis than when the cancer is localised to the breast

Newly published data in the May issue of Annals of Oncology, Oxford University Press show that after two years of post-surgical therapy, postmenopausal women with hormone-sensitive early breast cancer treated with Femara experienced 30 percent fewer early breast cancer recurrences at sites away from the breast (distant metastases) compared with tamoxifen(1).

The spread of breast cancer to other parts of the body means that it is extremely likely that a woman will die from the disease(2). Recurrences that occur locally, regionally, or in the opposite breast (contra-lateral) are more easily treated than those that spread far from the original tumour, and they are associated with better long-term outcomes(3,4).

In the retrospective analysis of more than 7,700 women at a median follow-up of two years, approximately 75 percent of early recurrences occurred at distant sites such as bone or vital organs. However, there were 30 percent fewer distant recurrences in the Femara group than in the tamoxifen group (87 vs. 125, respectively)(1).

Maria Leadbeater, Secondary Breast Cancer Nurse Specialist at Breast Cancer Care commented, "Breast Cancer Care speaks to women with breast cancer daily and knows that they welcome any treatment development that could help to reduce the likelihood of their cancer recurring. Having been treated for breast cancer the first time round, one of the greatest fears is that the disease might return. These findings confirm earlier results from this trial, and suggest that Femara may be a treatment option for postmenopausal women with early breast cancer that could help reduce the risk of this happening to them."

Compared wit
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
2. Newly Published Data from Large Study Support Cardiovascular Safety of Avandia (Rosiglitazone Maleate)
3. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
4. Adding Thalidomide to Standard Therapy Improves Survival in Newly Diagnosed Multiple Myeloma Patients Over Age 75
5. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
6. ECOG Phase III Newly Diagnosed Multiple Myeloma Trial (E4A03) Reports Lenalidomide Plus Low-Dose Dexamethasone Suggests Survival Advantage for Patients with Multiple Myeloma
7. MRI Detects Cancers in the Opposite Breast of Women Newly Diagnosed with Breast Cancer
8. Nymox Announces Positive Results from Newly Completed Long-term Study of NX-1207 for Benign Prostatic Hyperplasia
9. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
10. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
11. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
Post Your Comments:
(Date:9/22/2014)... Research and Markets has ... Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market ... offering. On the basis of ... has been divided into eight major segments, namely, ... hydromechanical ablation technologies. The light/laser ablation technology segment ...
(Date:9/22/2014)... Sept. 22, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ... fiscal 2014 ended July 31, 2014 on Monday, September 29 ... discuss the results at 11:00 AM ET. Participating in the ... Andrew A. Krakauer , President and CEO; Jorgen B. ... Sheldon , Senior Vice President, CFO and Treasurer; and ...
(Date:9/22/2014)... NORTH CHICAGO, Ill. , Sept. 22, 2014 ... that data from several clinical studies evaluating potential ... be presented at the upcoming 2014 European Society ... in Madrid, Spain . Data ... study evaluating the safety and efficacy of veliparib ...
Breaking Medicine Technology:Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 2Global Ablation Technologies (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave) Market - Forecasts to 2019 3Cantel Medical Corp. To Hold Conference Call To Discuss Results For Its Fourth Quarter And Fiscal 2014 Ended July 31, 2014 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 2AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 3AbbVie to Present Clinical Study Data on Potential New Oncology Medicines at the 2014 European Society of Medical Oncology Annual Meeting 4
... Ad, " This is Medicare and America at ... WASHINGTON, Dec. 9 The SCOOTER Store today launched a ... and cost savings associated with Medicare,s Power Mobility Benefit, which ... to receive power wheelchairs. , With budget cuts likely in ...
... , ROCKVILLE, Md., Dec. 9 Novavax, Inc. (Nasdaq: ... closed its previously announced public offering of 6,800,000 shares of ... net proceeds from the sale of the shares, after underwriting ... which will be used for preclinical studies and clinical trials ...
Cached Medicine Technology:The SCOOTER Store Launches New Advertising Highlighting the Value and Cost Savings From Medicare's Power Mobility Benefit 2NOVAVAX Announces Closing of Public Offering of 6,800,000 Shares of Common Stock 2
(Date:9/22/2014)... Rockville Centre, NY (PRWEB) September 22, 2014 ... Goodwin, before whom all of the federal mesh ... Boston Scientific Corp. have been consolidated for pretrial ... re: Boston Scientific Corp. Pelvic Repair System Products ... Southern District of West Virginia; Case no. 2:12-md-02326)—requiring ...
(Date:9/22/2014)... News) -- Teens and young adults at risk for ... help prevent risky sexual behaviors, according to new recommendations ... year, about 20 million new sexually transmitted infections such ... About half involve people between 15 and 24 years ... new report, published Sept. 22 in Annals of ...
(Date:9/22/2014)... September 22, 2014 Manhattan residents who ... side of the hip , which could be bursitis ... This treatment is now offered at New York Dynamic ... called trochanteric bursitis, occurs when the trochanteric bursa becomes ... in the hip, between the iliotibial band and the ...
(Date:9/22/2014)... to 40 percent of patients undergoing breast cancer surgery ... all the cancerous tissue in the initial operation. However, ... tested a tool they developed that will help surgeons ... decreasing the chances for repeat operations. ... September 22, 2014 in the Proceedings of the ...
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) South Asians living ... and double the rate of diabetes compared with while ... was published today in the Canadian Medical Association ... http://www.cmajopen.ca/content/2/3/E183.full , One of the fastest-growing ethnic ... million South Asian people living in Canada, comprising about ...
Breaking Medicine News(10 mins):Health News:Federal Court Sets Trial Date for Boston Scientific Vaginal Mesh Cases in Florida, the Rottenstein Law Group LLP Reports 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 2Health News:Behavioral Counseling Urged for Teens, Young Adults at Risk for STDs 3Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 2Health News:DNR Clinic Offers Hip Bursitis Treatment in Manhattan 3Health News:The fine line between breast cancer and normal tissues 2Health News:Higher risk of heart disease for South Asians in Canada 2
... 19 /PRNewswire-FirstCall/ - Notification of Year End,2007 Earnings Webcast ... (TSX: RBM) Year End 2007 Earnings Webcast and ... To listen to this Webcast and Conference Call ... To participate in the live conference call please dial ...
... Using the Canadian Light Source synchrotron, an international team led ... detailed structure of the enzyme the Norwalk virus uses to ... itself. The information is crucial to developing drugs that could ... viruses. , The Norwalk virus uses the enzyme, RNA ...
... (OTC,Bulletin Board: RXEI), a developer, manufacturer, and marketer of ... its,2007 year-end financial results in a conference call on ... Company will release its 2007 year-end financial results after ... call will be,RxElite CEO Jonathan Houssian, COO Earl E. ...
... ST. LOUIS, March 18 Sigma-Aldrich (Nasdaq:,SIAL) announced ... its $300 million,revolving credit facility established in December ... feature. Under the revised $450 million,revolving credit facility, ... and,$420 million will mature on December 11, 2012. ...
... The Pharmaceutical Care,Management Association (PCMA) issued the ... that are being,debated in Congress:, "PCMA ... drug,therapies is an important tool in promoting ... way with Pharmacy & Therapeutics,(P&T) committees and ...
... mental acuity may actually improve , , TUESDAY, March 18 ... treatment, head-and-neck cancer patients experience decreases in their physical ... quality of life, says a U.S. study. , ... that head and neck cancer treatment such as feeding ...
Cached Medicine News:Health News:Scientists see Norwalk virus' Achilles heel 2Health News:RxElite Inc. Fourth Quarter and Year-End 2007 Earnings Release and Conference Call Notice 2Health News:Head and Neck Cancer Outcomes a Mixed Bag 2
... The new Amsco 3080/3085 SP Bariatric ... width capacity and expanded surgical capabilities for ... extensions are rated for patients up to ... and easy attachment and full positioning capability. ...
... The new Amsco 3080/3085 SP Bariatric Foot ... capacity and expanded surgical capabilities for Amsco ... The Amsco Foot Extension is rated for ... designed for secure and easy attachment and ...
... The Pulsavac Plus System offers a ... Debridement System. High power efficiently clears bone ... Specific tips are available for hip and ... a wide range of pressure options for ...
The Simpulse Solo Pulsed Lavage System requires minimal set up and has a Wide range of tips available for every orthopaedic procedure. It uses a separate suction lumen to reduce clogging and n ergono...
Medicine Products: